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phology. One of the remaining concerns is uncertainty
about the long-term effect of persistent blood flow within
the aneurysm sac after endovascular grafting, an occur-
rence known as endoleak.1 In fact, endoleak development
constitutes one of the prime reasons to perform postoper-
ative surveillance by regularly performed image studies,
usually computed tomography (CT) scanning.2-4 The
main purpose of EAR is to prevent death from rupture of
the aneurysm, and early identification of endoleaks is
intended to help obtain this goal. Protocols for when and
how to manage endoleaks have been suggested, despite
conflicting opinions on the natural history of endoleaks.5
Several investigators consider the presence of perigraft
flow to be evidence of failed treatment because it may pre-
dict aneurysmal enlargement and eventual rupture.6-8 A
contrasting opinion was presented in a recent study in
which no relation between early endoleaks and late rup-
ture, conversion to open surgery, and death could be
demonstrated.9 From this latter report, it might be con-
cluded that the observation of perigraft flow had little
consequence for the ultimate fate of the patient.
Clinical management of endoleak may differ between
types of endoleak. A generally accepted classification dis-
Although the durability of endovascular repair of
abdominal aortic aneurysms (AAAs) (EAR) is not defini-
tively established, this treatment method is increasing in
popularity among patients and doctors. Physicians from
different vascular-oriented disciplines have engaged in
workshops and training sessions to learn how to perform
the technique in patients with suitable aneurysm mor-
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Objective: The purpose of this study was to assess the incidence, risk factors, and consequences of endoleaks after
endovascular repair of abdominal aortic aneurysm.
Methods: Data on 2463 patients were collected from 87 European centers and recorded in a central database. Preoperative
data were compared for patients with collateral retrograde perfusion (type II) endoleak (group A), patients with device-
related (type I and III) endoleaks (group B), and patients in whom no endoleak was detected (group C). Only endoleaks
observed after the first postoperative month of follow-up were taken into consideration. Regression analysis was per-
formed to investigate statistical relationships between the occurrence and type of endoleak and preoperative patient and
morphologic characteristics, operative details, type of device, and experience of the operating team. In addition, postop-
erative changes in aneurysmal morphology, the need for secondary interventions, conversions to open repair, aneurys-
mal rupture, and mortality during follow-up were compared between these study groups.
Results: Patients in group A had a higher prevalence of a patent inferior mesenteric artery compared with patients with-
out endoleak. Patients in group B were treated more frequently than patients in group C by an operating team with
experience of less than 30 procedures. The mean follow-up period was 15.4 months. Secondary interventions were
needed in 13% of the patients. Rupture of the aneurysm during follow-up occurred in 0.52% (1/191) in group A,
3.37% (10/297) in group B, and 0.25% (5/1975) in group C. Life table analysis comparing the three study groups
demonstrated a significantly higher rate of rupture in group B than in group C (P = .002). The incidence of conver-
sion to open repair during follow-up was higher in group B than in the other two study groups (P < .01). Death was
related to the aneurysm or to endovascular repair of the aneurysm in 7% of patients. Secondary outcome success,
defined as absence of rupture and conversion, was significantly higher in group A and C compared with that in group
B (P = .006 and P = .0001, respectively).
Conclusions: The presence of device-related endoleaks correlated with a higher risk of aneurysmal rupture and conver-
sion compared with patients without type I or III endoleaks. Type II endoleak was not associated more often with these
events. Consequently, intervention in type II endoleak should only be performed in case of increase of aneurysm size.
(J Vasc Surg 2002;35:461-73.)
criminates endoleaks according to the site of the flow into
the aneurysmal sac.6 Inadequate seal at the proximal or dis-
tal segments of the endoprosthesis is defined in type I
endoleak, whereas branch flow through a patent inferior
mesenteric artery (IMA), lumbar artery, or hypogastric
artery is indicated as type II. Midgraft endoleaks, either
through fabric holes or from inadequate seal between endo-
graft components, is defined as type III endoleak. Leaks of
types I and III are considered to constitute a major compli-
cation, potentially leading to aortic rupture, whereas type II
endoleaks appear to potentiate aneurysm enlargement to a
lesser extent.2,10-13 However, aneurysmal rupture or severe
symptoms necessitating secondary abdominal surgery have
been reported in 41% of patients with collateral backflow
after conventional operative aortic exclusion without side-
branch ligation, a situation comparable with endovascular
repair.14 Moreover, anecdotal evidence that type II
endoleak may be responsible for late rupture after EAR has
been reported.15 Because of these conflicting opinions,
treatment practice with regard to the management of active
side branches varies from a strictly conservative policy to
active obliteration by coil embolization.16,17
Analysis of the fate of endoleaks by using an extensive data
set of a large patient series may lead to greater consensus
about treatment protocols. The present study was undertaken
to examine the collective experience of 87 European institu-
tions collaborating within the EUROSTAR project. The
objective was to assess whether specific preoperative patient
characteristics, aneurysmal morphologic features, and opera-
tive aspects constituted risk factors for the development of
postoperative endoleak. In addition, patients with different
types of endoleak and patients without endoleak were com-
pared with regard to the occurrence of several major outcome
events during follow-up, including aneurysmal enlargement,
rupture, conversion to open repair, and death of the patient.
METHODS
Patients and organization of registry. A detailed
account of the organization of the EUROSTAR Registry
and a report on early complications after EAR have been
published previously.18,19 In summary, the EUROSTAR
Registry was established in 1996 for the purpose of colla-
tion and analysis of data from patients having endovascular
treatment for AAA. A study protocol and case record forms
were designed by an international Steering Committee.18
The inclusion criteria, as defined in the registry’s protocol,
comprised elective treatment for AAA and vascular
anatomy suitable for the implantation of a stented tube or
bifurcated prosthesis. Baseline data on suitable patients
were recorded by the participating institutions on case
record forms and submitted for inclusion to the Data
Registry Center. Findings at follow-up visits, which
involved clinical examination and CT, were recorded on
data forms and returned at regular intervals to the Data
Registry Center for processing and analysis. In the case of
confusing data, individual centers were contacted by the
registry center for clarification. There was no outside mon-
itoring of the centers or involvement of a regular core lab-
oratory for the evaluation of CT scanning or other imag-
ing studies.
Data from 2964 patients who had EAR between July
1994 and July 2000 were assessed. In 462 patients, enroll-
ment was retrospective, and in 2502 patients who under-
went surgery after September 1996, enrollment was
prospective. In one patient, the procedure was cancelled
before it took place; the aneurysm ruptured in one patient
before the planned endograft placement; and in three
patients, the procedure was aborted. The 1-month mortal-
ity on intention-to-treat basis was 2.9% (85 patients). Early
conversion to open surgery was performed in 55 patients
(1.9%), 47 at the time of the initial procedure and 8 at a
secondary operation within the first postoperative month.
For 356 patients, no first-month follow-up data were avail-
able yet in July 2000. In 70 of these patients, enrollment
had been more than 3 months before, and these patients
were considered to be lost to follow-up. The number of
patients that had a recorded follow-up of 1 month or more
was 2463, and this cohort formed the basis of this study.
Patients were treated in 87 centers in 17 countries. The
mean follow-up period was 15.4 months (range, 1-72
months). A total of 7927 postoperative visits was recorded
with a mean of 3.2 visits per patient (range, 1-9).
CT with contrast enhancement of the abdominal
blood vessels was the most frequently used method of
imaging at follow-up visits (in 94% of patients). However,
contrast angiography (in 1% of patients), magnetic reso-
nance angiography (in 2% of patients), and duplex imag-
ing (in 3% of patients) were also used at the discretion of
the responsible physicians. For this analysis, data from one
examination (the first in ranking order—[1] CT, [2] con-
trast angiography, [3] magnetic resonance angiography,
[4] duplex imaging) per visit were included. Plane abdom-
inal radiograph studies were not included in this analysis,
because this examination was performed in a relatively
small proportion of patients.
Assessed variables and outcome events. All endo-
leaks that were identified at 1 month and thereafter were
included in the analysis. Endoleaks at the completion
angiography were not considered. Endoleaks were classi-
fied according to the scheme proposed by White et al6 as
follows: type I involved endoleaks originating from the
attachment site at the proximal infrarenal aortic neck or
from the distal site of the endograft at the iliac or aortic
bifurcation level; type II involved reperfusion endoleaks
from the inferior mesenteric, lumbar, accessory renal,
sacral, and hypogastric arteries; and type III included
endoleaks from the endograft itself, either from fabric
holes or from connections between different modules.
Porosity of the fabric was not recorded, because this was
not observed after the early postoperative period. In
cases in which different types of endoleaks were observed
at different follow-up periods, types I and III were con-
sidered above type II for the analysis. The interval
between the date of surgery and the date on which an
endoleak was identified for the first time was used for life
table analysis.
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Anatomic dimensions that were recorded include the
diameter at the midportion of the infrarenal neck, the
aneurysm diameter measured at its largest section from
outer wall to outer wall across the minor diameter on the
axial CT slice, the free aneurysmal lumen measured as the
inner diameter of the thrombus lined lumen, and the dis-
tance between the lower renal artery and the aortic bifur-
cation. In addition, significant angulation according to the
judgement of the participating physicians was recorded at
the neck, aneurysm, or iliac levels. Enlargement of the
aneurysmal neck was defined as a diameter increase of 3
mm or more. Aneurysmal enlargement was defined as a
diameter increase of at least 8 mm relative to the preoper-
ative measurements. The maximum recorded aneurysm
diameter during follow-up was taken for this analysis, and
any subsequent smaller diameter that may have occurred
because of endoleak treatment was omitted.
Adverse events that were recorded during follow-up
include death of the patient, rupture of the aneurysm, and
requirement of a secondary intervention. In patients who
underwent multiple procedures, only the most extensive
procedure was taken into account, according to the fol-
lowing ranking: transabdominal, femorofemoral, and
endovascular reintervention. Device migration, endograft
occlusion, and the causes of death were tabulated and used
to provide background information. Results are reported
as means and ranges or as percentage of patients with dis-
crete variables. Preoperative patient characteristics, comor-
bid factors, aneurysmal morphology at the time of the
initial procedure, patency of side branches, and details
regarding the procedure and devices were correlated with
the defined study groups by univariate analysis.
Subsequent adjustments in these correlations were made
for the year the procedure took place and whether proce-
dural data were retrospectively recorded in the database.
Differences in findings between study groups were
assessed by χ2 tests for discrete variables and by Mann-
Whitney tests for continuous variables. Presence and type
of endoleaks were correlated with the endograft brands
used in the series, and different devices were compared
among each other. For this purpose, a multivariate analy-
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sis was performed with adjustment for the duration of fol-
low-up (occurrence of endoleak being the event), the year
in which the procedure was performed, and whether the
team experience involved less than 30 procedures. A P
value <.05 was considered to represent a significant differ-
ence. Cumulative rates of freedom from endoleaks, sec-
ondary interventions, conversion to open repair, and
aneurysmal rupture were assessed by life table analysis.
Significant differences between study groups were assessed
by log-rank testing. Primary and secondary outcome suc-
cess was defined by using criteria similar to those used by
Zarins et al9 to allow a comparison with the results of the
present study. Primary outcome success was defined as
absence of death, no aneurysm rupture, no conversion to
open repair, and no secondary intervention. Secondary
outcome success was defined as absence of death, no
aneurysmal rupture, and no conversion to open repair. In
addition, secondary outcome success not incorporating
death in the composite endpoint was determined. All sta-
tistical analysis were performed with SAS statistical soft-
ware (version 6.12, SAS Institute, Inc, Cary, NC).
RESULTS
Postoperative endoleaks. Of the 2463 patients who
constituted the study cohort, 171 had an endoleak at their
first month postoperative assessment and 317 patients had
a new-onset endoleak, identified at a later date. In total,
there were 488 (19.8%) patients in whom an endoleak was
observed at any time after the endograft implantation.
Three groups were distinguished—group A including 191
patients (7.8%) with a type II endoleak, group B consisting
of 297 patients (12%) with type I or III or multiple
endoleaks with a combination of different types, and group
C, consisting of 1975 patients who never had an endoleak.
A new-onset endoleak was observed in 129 patients (67%)
in group A and in 188 patients (63%) in group B.
Preoperative patient characteristics, aortoiliac mor-
phologic features, operative details, and device brands
used are summarized in Tables I through IV. The inci-
dence of current or recent smoking was less in patients
with type II endoleaks than in other patients (Table I).
Table I. Characteristics and comorbid factors of 2463 patients with EAR
Group A, type II endoleak Group B, type I/type III Group C, no endoleak
Characteristics and comorbid factors (191 patients) endoleak (297 patients) (1975 patients)
Age in mean years (range) 71.7 (50-89)* 71.0 (42-90)* 70.0 (37-92)*
Male sex 91.1% 89.2% 92.8%
ASA physical status classification
ASA I 5.5% 11.6% 8.8%
ASA II 40.7% 35.5% 37.4%
ASA III and IV 53.8% 52.9% 54.8%
Diabetes 11.1% 11.4% 10.1%
Smoking 38.4%† 51.3%† 59.1%†
Hypertension 55.5% 58.2% 58.8%
Cardiac history 63.9% 62.5% 57.8%
*P = .0001.
†P = .01 to .001.
ASA, American Society of Anesthesiologists.
The aneurysmal neck was slightly wider in group B, and
the aneurysm diameter was larger in groups A and B as
compared with group C. Significant angulation of the
infrarenal neck was associated with endoleak. A smaller
amount of thrombus in the aneurysmal sac correlated with
device-related endoleaks. Type II endoleak correlated with
higher prevalence of IMA patency (Table II). Patients in
group B were treated by a team with experience of less
than 30 EARs more often than patients without endoleak.
Endoleak at completion of the procedure and migration
correlated with a higher percentage of endoleaks during
follow-up in groups A and B (Table III). Patients with a
Vanguard (Boston Scientific, Natick, Mass) device more
often had a type II endoleak than patients with Talent
(Medtronic AVE, Sunrise, Fla) or with Zenith (Cook,
Bjaeverskov, Denmark). Patients who received an
EVT/Ancure device (Guidant, Menlo Park, Calif) were
more likely to develop a type I or III endoleak compared
with patients with Vanguard or AneuRx (Medtronic AVE,
Cupertino, Calif) devices (Table IV).
Change of aneurysm morphology. The mean preop-
erative neck diameter in the entire series was 22.7 mm, and
after 2 years this mean diameter had increased to 24.0 mm.
The proportion of patients with an increase greater than 3
mm varied from 23.4% to 39.4% in the three study groups,
and the differences were not statistically significant.
The distance between the lowest renal artery and the
aortic bifurcation in the whole series reduced from a pre-
operative mean of 116.0 mm to 113.3 mm at 2 years. The
changes in this dimension did not differ statistically
between the study groups.
The mean aneurysm diameter decreased in the group
of 2109 patients in whom serial data were available from a
mean value of 55.9 mm preoperatively to 50.1 mm after 1
year and 48.9 mm after 2 years. In group A, the aneurysm
diameter increased by more than 8 mm in 9.8% (18/184)
of the patients, in group B, in 19.8% (50/253) of patients,
and in group C, in 5.4% (91/1672) of patients. The
cumulative rates of patients with enlargement of the
aneurysm of 8 mm or greater at 2 years were 15%, 18%,
and 7% in groups A, B, and C, respectively. There was a
significantly smaller proportion of patients with aneurysm
enlargement in group C compared with the other groups
(P = .0001) (Fig 1). The difference between groups A and
B was not significant. In group A, the rate of aneurysm
enlargement increased rapidly from 15% to 41% after the
third year. However, at this follow-up, the standard error
had increased to greater than 10%, precluding any firm
conclusions with regard to late growth in this group.
The 91 patients in group C who demonstrated
enlargement of aneurysm diameter had presumed
endotension without detectable endoleak. None of these
patients had documented rupture of his or her aneurysm,
but 6.6% (6) died during follow-up. There were no differ-
ences in the rupture and death rates compared with those
of patients in group C without aneurysmal growth.
However, the conversion rate for these patients was 3.3%
(3 patients), which was significantly greater than the 0.4%
(7/1581) conversions in the other patients in group C
without evidence of endotension (P = .0001).
Secondary interventions, conversion to open repair.
Three hundred fifty-five reinterventions of any type after
the first postoperative month were performed in 320
patients (13% of the entire cohort). These interventions
consisted of a transfemoral endovascular procedure in 249
patients, femorofemoral crossover bypass in 48 patients,
and transabdominal procedures in 58 patients. Of this latter
category, 50 were conversions to open repair. In group A,
the number of patients with secondary interventions was 42
(22.0%), in group B it was 160 (53.9%), and in group C it
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Table II. Dimensions and variables representing aneurysm morphology at preoperative assessment in 2463 patients
with EAR
Group A, type II endoleak Group B, type I/type III Group C, no endoleak
Variable (191 patients) endoleak (297 patients) (1975 patients)
Neck diameter (mm) (mean [range]) 22.5 (15-30) 22.9 (15-30)* 22.6 (12-40)*
AAA diameter (mm) (mean [range]) 57.3 (39-95)† 57.0 (26-89)† 55.6 (26-150)†
Length of aneurysm (mm) (mean [range]) 116.6 (65-180) 116.8 (51- 165) 115.8 (30-265)
Significant angulation
Infrarenal neck 24.1%‡ 21.5%‡ 19.5%‡
Aneurysm 11.0% 7.4% 10.5%
Right iliac artery 38.7% 29.3% 33.0%
Left iliac artery 41.4% 33.3% 38.3%
Thrombus (percent thrombus of 26.2 (0-70) 23.1 (0-60)§ 27.7 (0-80)§
maximum aneurysmal diameter) 
(mean [range])
Hypogastric arteries patent (% pts) 85.9% 77.8% 85.4%
IMA patent 40.3%|| 30.6% 31.0%||
*P = .009.
†P = .01 to .0001.
‡P = .02 (for groups A and B combined versus group C).
§P = .009.
||P = .01.
was 118 (6.0%). Life table analysis demonstrated a freedom-
from-secondary-intervention rate that was significantly
lower in groups A and B than in group C (P = .001 for all
group differences). At 2 years, the rates were 61.1%, 41.1%,
and 91.3% for groups A, B, and C, respectively (Fig 2).
If only freedom from transfemoral reinterventions was
considered, it was lower in groups A (65.4% at 2 years)
and C (49.2% at 2 years) than in group B (94.0% at 2
years) (P = .0001 for group A versus group C and for
group B versus group C; P = .001 for group A versus
group B). A detailed survey of the data revealed that in
174 (69.9%) of the cases in which transfemoral reinter-
ventions were performed, an endoleak was involved.
Conversions to open aneurysm repair were performed
urgently for rupture in 12 patients and electively in 38
patients. Indications for elective conversions were
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endoleak in 20 patients, migration in 11 patients, endo-
graft occlusion in 5 patients, aneurysmal growth in 5
patients, symptomatic aneurysm in 3 patients, and device
damage in 2 patients. Eight patients had two indications
for conversion. Conversions were more frequent in group
B (32 patients, 10.8%) than in group A (3 patients, 1.6%)
and group C (15 patients, 0.8%). The cumulative freedom
from conversion (elective and urgent) at 2 years was
97.4%, 89.6%, and 99.0% for groups A, B, and C, respec-
tively (P = .0001 overall; P = .14 for group A versus group
C; P = .0001 for group B versus group C; P = .012 for
group A versus group B) (Fig 3).
Aneurysm rupture. Sixteen patients had a rupture of
their aneurysm at a mean of 15.7 months postoperatively
(range, 3-36 months). In group A, one patient (0.52%)
had aneurysmal rupture, in group B, 10 patients (3.37%)
Table III. Procedural details in 2463 patients with EAR
Group A, type II endoleak Group B, type I/type III Group C, no endoleak
Procedural details (191 patients) endoleak (297 patients) (1975 patients)
Configuration of device
Bifurcated 96.9 92.3 92.8
Straight 0 6.1 3.9
Aorto-uni-iliac 3.1 1.7 3.3
Adjunct procedures* 29.3 26.3 32.7
Team experience <30 procedures 40.3 62.0† 44.5†
Hypogastric artery overlapped by device limb 18.3 15.1 14.2
Endoleak present at completion of operation‡ 21.5§ 31.0§ 10.6§
Device extensions used|| 23.4 24.8 18.5
Migration of device during procedure 2.1¶ 1.7¶ 0.7¶
*Combined endovascular and surgical adjunct procedures.
†P = .0003.
‡Endoleak type I, II, or III or a combination.
§P = .0001.
||Aortic or iliac segment extensions.
¶P = .003 to .0001.
Table IV. Device brands used in 2493 patients with EAR
Group A, Group B, Group C,
type II endoleak type I/type III no endoleak
Device brand Entire cohort (191 patients) endoleak (297 patients) (1975 patients)
Vanguard 823 86 (10.4)*† 109 (13.2)‡ 628 (76.3)
AneuRx 607 55 (9.1) 40 (6.6)§ 512 (84.3)
Talent 315 19 (6.0)* 29 (9.2) 267 (84.8)
Stentor|| 267 4 (1.5) 72 (27.0) 191 (71.5)
EVT/Ancure 108 9 (8.3) 24 (22.2)‡§ 75 (69.4)
Excluder¶ 104 8 (7.7) 6 (5.8) 90 (86.5)
Zenith 192 9 (4.7)† 10 (5.2) 173 (90.1)
Other 47 1 (2.4) 7 (11.9) 39 (85.7)
Numbers in parentheses represent percentage of patients in each device group that had a type II endoleak, a type I/III endoleak, or no endoleak (group
A, group B, or group C, respectively).
See “Methods” section for description of the analysis to determine differences in occurrence of type II or type I/type III endoleaks between device brands.
*P = .014 (relative risk, 1.9).
†P = .009 (relative risk, 2.6).
‡P = .029 (relative risk, 1.7).
§P = .001 (relative risk, 2.4).
||Mintec, Freeport, Bahamas.
¶Gore, Flagstaff, Ariz.
did, and in group C, five patients (0.25%) did. The cumu-
lative rate of rupture in group B (4.0% at 2 years) was sig-
nificantly higher than in group C (0.7% at 2 years, P =
.0001) (Fig 4). There was no statistical difference in the
rupture rate between groups A (1.8% at 2 years) and C (P
= .54). Despite a higher prevalence of rupture in group B,
the difference in the rate of rupture between groups A and
B failed to reach statistical significance (P = .10). Before
rupture, the aneurysm diameter was 6 cm or larger in 7 of
the 16 patients with rupture, whereas the aneurysm had
enlarged by more than 8 mm in two patients.
Mortality and primary procedural and secondary
procedural outcomes. One hundred seventy-two patients
died during follow-up. The mean period between surgery
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Fig 1. Cumulative rates of patients with enlargement ≥8 mm of AAA in group A, group B, and group C. Dashed line indicates standard
error >10%.
and death was 15.1 months (range, 3-48 months). The
overall 2-year cumulative survival rate was 90%. There was
no statistical difference in survival among the three study
groups. Twelve (7.0%) of the patients died of causes related
to either the aneurysm or EAR. These causes included rup-
ture of the aneurysm in 8 patients, infected endograft in 2
patients, endograft thrombosis in 1 patient, and postoper-
ative death following conversion for a symptomatic, grow-
ing aneurysm in 1 patient. Of the patients that died of
rupture, six were in group B and two were in group C.
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One hundred sixty (93.0%) patients died of unrelated
causes—47 of cardiac causes, 43 of malignancies, 13 of
strokes, 13 of pulmonary disorders, 6 of infectious
processes, 12 of miscellaneous causes, 6 of unknown but
unrelated to the aneurysm causes, and 20 of completely
unknown causes.
The cumulative primary outcome success at 2 years
was 72.9% in the overall series, 54.7% in group A, 39.7%
in group B, and 90.0% in group C (P = .0001 to .0003
for any group comparison). Two-year secondary out-
Fig 2. Freedom-from-secondary-intervention rates in group A, group B, and group C.
come success was 88.0% in all patients, 84.5% in group
A, 85.3% in group B, and 89.0% in group C. Only
groups B and C differed significantly (P = .04). If death
was not included, the secondary 2-year success rate was
97.4%, 88.9%, and 98.9% for groups A, B, and C,
respectively. The difference in secondary outcome suc-
cess omitting death between group A versus group B
and group B versus group C was significant (P = .006
and .0001, respectively), whereas there was no differ-
ence between groups A and C.
DISCUSSION
The primary indication for EAR is to prevent death
from aneurysm rupture. Ideally, the goal is to eliminate
the possibility of rupture, but rupture after endograft
placement appears to occur in at least 1% of the cases
annually, as has been pointed out in a recently published
EUROSTAR report.20 This report in fact confirmed sev-
eral previous anecdotal reports and clinical studies in
which incomplete protection by EAR against progressive
aneurysm growth and rupture was observed.11,21-26 The
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Fig 3. Freedom from conversion to open surgery in group A, group B, and group C.
incidence of this event is related not only to the complex-
ity of aneurysm morphologies treated, but also to variables
that are currently less well characterized, including
endoleaks and endotension.2-6,27-29 There is an increasing
number of reports proposing that the presence of endoleak
in fact equals failure of treatment. Endoleaks have the
potential to increase aneurysmal sac size and intraluminal
pressure and possibly lead to late rupture.30-32 In the pre-
sent report, we have focused on the relation of endoleak
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 3 van Marrewijk et al 469
and endotension with the risk of rupture, death, and the
need for secondary interventions in a large collaborative
series of patients who had their data collated in the
EUROSTAR database. The first-month results were not
detailed here because they were the subject of a previous
report.19 In addition, it was considered that 50% to 60%
of endoleaks at completion of EAR demonstrate sponta-
neous closure within the first postoperative month, and
only a minority seal after this period.3,19,33
Fig 4. Freedom from aneurysm rupture in group A, group B, and group C.
Of the preoperative morphologic factors, aneurysm
size, angulation of the infrarenal neck, patency of IMA,
and the amount of sac thrombus were found to be associ-
ated with increased occurrence of endoleaks. In the pres-
ent study, type I and type III endoleaks occurred less
frequently in the presence of mural thrombus. Others
found that type II endoleak from lumbar arteries occurred
less often in patients with a significant volume of throm-
bus in the sac.2,32 In one of these studies it was observed
that no endoleaks from the lumbar arteries occurred in
patients with thrombus at the dorsal site of the
aneurysm.32 In the present study, no distinction was made
between different localization of intrasac thrombus.
Some differences between endografts were noted.
Type II endoleaks were more frequent with the use of a
Vanguard device than with Talent or Zenith. It can be
speculated whether different viscoelastic properties of the
endograft have any influence. Compliant grafts may trans-
fer volume changes synchronous to the cardiac cycle to the
stagnant blood within the aneurysm sac, perhaps main-
taining side branch patency.6,34
The prevalence of endoleaks during follow-up was
approximately 20%, which is in agreement with the persis-
tent endoleak rates observed in other studies.3,33 In 7% of
patients, endoleaks were present at the first-month post-
operative visit, whereas in 13%, they developed later dur-
ing follow-up. Matsumura and Moore3 observed a greater
tendency for growth in aneurysms with de novo
endoleaks, and these authors suggested that this category
may represent a separate entity of endoleaks in which fib-
rinolysis of initially occluded channels might have taken
place. It may be of interest to examine whether a propor-
tion of endoleaks that occur late are in fact initial
endoleaks that reappear. This aspect was not investigated
here but needs to be addressed in a future study.
Occasionally, the presence of type II endoleak is hard
to demonstrate. Delayed CT examination with 3-mm
slices is probably the best technique to demonstrate col-
lateral reperfusion, and it is definitively better than stan-
dard CT.2,35 In this multicenter registry, in which CT
technique was not uniform, there is a possibility for under-
diagnosis of type II endoleak. Not infrequently, collateral
endoleaks present in combination with device-related
types of endoleak.2,20 In this study, we have separated iso-
lated type II endoleaks from combined endoleaks, which
were relegated to group B together with single inflow-site
device-related endoleaks. Our premise was that collateral
endoleaks may follow a course different from that fol-
lowed by graft-related leaks. Moreover, most workers in
the field, including ourselves, held the view that the pre-
ferred treatment of type II endoleaks is primarily conserv-
ative, whereas type I and type III endoleaks need a more
aggressive approach.
Studies of AAA morphology after endografting have
shown that a certain degree of aneurysm remodeling does
occur postprocedurally.31,36,37 Morphologic neck changes
also occur after open AAA repair.37 A change in AAA
diameter during follow-up was the principal change in
morphology. Decrease in size is often used as an indicator
of complete aneurysm exclusion. Conversely, if an
endovascular-treated aneurysm fails to shrink, it is consid-
ered an ominous sign, suggesting that an endoleak might
be present. Analysis of interobserver and intraobserver
variability in evaluating aneurysm size from CT scanning
has shown that a 5-mm threshold would represent an
actual change in the aneurysm rather than a measurement
error.38 Other reports have used different standards for
aneurysm change after different periods, making them dif-
ficult to compare. We have defined enlargement of the
aneurysm as a diameter increase of 8 mm or greater. The
larger threshold was chosen because of a presumably larger
interobserver variability in the large number of institutions
participating in the registry compared with a single insti-
tution assessment.
There were significant differences in aneurysm
changes during follow-up, in that patients with device-
related and collateral endoleaks had a significantly higher
incidence of increase in size than patients who never had
endoleaks. It appears that the incidence of growth
increased after 2 years in patients with collateral endoleaks.
However, at that point of follow-up the number of
patients was small, precluding any definite conclusions
regarding growth in this subgroup. These findings differ
from those of a recent study by Resch et al,2 who found
no statistical differences in aneurysm reduction in patients
with collateral endoleaks and total exclusion. It is note-
worthy that the incidence of enlargement was probably
influenced by the fact that interventions were often per-
formed to treat an endoleak, particularly in group B, on
the basis of endoleak detection alone, before the aneurysm
had the opportunity to grow.
An increase in the size of aneurysm was found in 5.4%
of all patients without a discernible endoleak, a prevalence
that has not been reported previously in the literature. The
pathogenesis of endotension without endoleak is uncer-
tain. Various mechanisms that have been suggested
include the presence of small, radiologically undetectable
endoleaks, pressure transmission from the adjacent endo-
graft lumen or through thrombotic “seals,” and fluid shift
caused by osmosis.28,29
Overall freedom from secondary intervention (trans-
femoral, crossover bypass, and conversion) was lower
(41% at 2 years) in patients with graft-related endoleak
than in patients with no endoleak or a type II endoleak
(91% and 61% at 2 years, respectively). Controversy
remains about the most appropriate management for
type II endoleaks. Coil embolization of the endoleak has
been used as treatment,2,16,17 whereas it has also been
performed as a preventive measure before endograft
implantation.39 Many physicians just observe and inter-
vene only if there is aneurysm expansion. Based on the
present findings, this is also our own recommendation.
Conversion to open aneurysm repair during follow-up
was most often performed in group B with a freedom-
from-conversion rate at 2 years of 89.6%. Endoleak was
the most frequent cause, followed by device migration.
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These findings correspond to a previous EUROSTAR
communication, in which 82% of patients with late con-
version had an endoleak.40
From the present results, it is apparent that graft-
related endoleaks (type I, type III, or a combination) are
associated with a significantly greater risk of rupture than
collateral perfusion (type II) endoleaks. Although this dif-
ference in behavior has been suggested previously,3.13 oth-
ers have challenged the concept of a strong correlation
between endoleaks and the risk of rupture. In their recent
study, Zarins et al9 have concluded that some patients who
have no endoleaks may decrease their aneurysm, and yet
the aneurysm may still rupture. This led them to conclude
that the primary outcome of success (ie, prevention of
rupture) was not necessarily associated with absence of
endoleak. These authors postulated that sacs that have a
late onset of acute repressurization expand their aneurysm
rapidly with an increased chance of rupture. Device migra-
tion, at either the proximal or distal extremities of the
graft or because of device component dissociation, may
occur without endoleak. In the few patients who had rup-
ture without endoleak, an impending dissociation of the
second leg was observed only when reviewing the plain
abdominal radiograph studies after the event. Stent-frame
breakage, which is hardly visible on CT, may cause insta-
bility of the attachment system. These manifestations of
device failure may result in migration and rupture occur-
ring in a rapid sequence.21-26 Plain abdominal radiograph
studies may be effective in the identification of impending
loss of integrity of exclusion of the aneurysm.41 Fabric
tears, as a cause of late rupture, have been described also,
and they may not be predicted by CT scanning.42 Thus,
we would concur with the observations of Zarins et al,9
that the relationship between endoleak and rupture is 
not absolute. In the more or less acute situations described
above, endoleak may be present only for a very short time,
not allowing detection at regular surveillance. Never-
theless, the correlation between endoleak and rupture in
the present study was indisputable, and it emphasizes the
importance of a large-scale database with sufficient statis-
tical power to demonstrate relationships between relatively
rare events.
Current criteria for success or failure are imperfect.
Death during follow-up is infrequently related to the
aneurysm. In the present study, 93% of the late deaths
were from causes unrelated to the aneurysm and were
instead the result of preexisting conditions or intercurrent
diseases typical for this population of patients. To include
death in a composite outcome measure will blur the pic-
ture if treatment effects in different study groups are com-
pared. Moreover, of the deaths related to late rupture, the
majority may become apparent first after a long follow-up
period, given the fact that endovascular-treated AAAs have
an annual rupture rate of 1% to 1.5%.20 To demonstrate
any statistical differences in death rates between groups,
many years of follow-up are required. Outcome events
other than death may include changes in aneurysm diam-
eter or volume detected at surveillance.43 A change in size
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probably reflects intrasac pressure (endotension) and may
be a reasonable parameter of success or failure of aneurysm
exclusion.32,43 However, an increase in size can be
detected only after a certain period of follow-up. The
duration of this time period is not known, yet a period of
6 months seems to be the minimum to avoid measure-
ment errors. However, interval ruptures have been
observed, and the uncertainty associated with observation
time may be a cause of concern for some patients. Direct
measurements of intrasac pressure would be the optimal
method for surveillance, but these measurements cannot
be made noninvasively at present.
In our view, the most practical parameters to represent
secondary outcome success at the current time are rupture
of the aneurysm and conversion to open repair. When
using these outcome measures, we found significantly
worse results in patients with device-related endoleaks
than in the other categories of patients.
CONCLUSION
In the present study, the occurrence of endoleak
observed during follow-up has been recorded and its rela-
tionship to hard endpoints assessed. Endoleak, although
in itself not a hard endpoint, predicted conversion or rup-
ture of the aneurysm, considering that 35 out of 50
patients with a conversion and 11 out of 16 patients with
rupture had an endoleak. Endoleak correlated with the
need for secondary intervention, a decision made on the
basis of clinical judgement by the responsible physicians in
this registry. These conclusions were only valid for device-
related endoleak. In patients with type II endoleak, clini-
cal outcome did not differ significantly from that of
patients who never had an endoleak. Accordingly, it is rec-
ommended that type II endoleaks be followed by regular
imaging and intervention performed only in case of sig-
nificant increase on aneurysm size.
REFERENCES
1. White GH, Yu W, May J. Endoleak—a proposed new terminology to
describe incomplete aneurysm exclusion by an endoluminal graft. J
Endovasc Surg 1996;3:124-5.
2. Resch T, Ivancev K, Lindh M, Nyman U, Brunkwall J, Malina M, et
al. Persistent collateral perfusion of abdominal aortic aneurysm after
endovascular repair does not lead to progressive change in aneurysm
diameter. J Vasc Surg 1998;28:242-9.
3. Matsumura JS, Moore WS. Clinical consequences of periprosthetic
leak after endovascular repair of abdominal aortic aneurysm. J Vasc
Surg 1998;27:606-13.
4. Wain RA, Marin ML, Ohki T, Sanchez LA, Lyon RT, Rozenblit A, et
al. Endoleaks after endovascular graft treatment of aortic aneurysms:
classification, risk factors, and outcome. J Vasc Surg 1998;27:69-80.
5. Greenberg R, Green R. A clinical perspective on the management of
endoleaks after abdominal aortic endovascular aneurysm repair. J Vasc
Surg 2000;31:836-7.
6. White GH, May J, Waugh RC, Yu W. Type I and type II endoleaks: a
more useful classification for reporting results of endoluminal AAA
repair. J Endovasc Surg 1998;5:189-93.
7. Raithel D, Heilberger Ph, Ritter W, Schunn C. Secondary endoleaks
after endovascular aortic reconstruction [abstract]. J Endovasc Surg
1998;(suppl I):I26-7.
8. Sunder-Plassmann L, Orend K, Görich J, Rilinger N, Pamler R. The
endoleak issue: main determinant of stent-graft future in endoluminal
AAA-repair [abstract]? J Endovasc Surg 1999;6:208.
9. Zarins CK, White RA, Hodgson KJ, Schwarton D, Fogarty TJ.
Endoleak as a predictor of outcome after endovascular aneurysm
repair. AneuRx multicenter clinical trial. J Vasc Surg 2000;32:90-107.
10. Parodi J. Endovascular repair of abdominal aortic aneurysms and
other arterial lesions. J Vasc Surg 1995;21:549-57.
11. Lumsden AB, Allen RC, Chaikof EL, Resnikoff M, Moritz MW,
Gerhard H. Delayed rupture of aortic aneurysms following endovas-
cular stent grafting. Am J Surg 1995;170:174-8.
12. Balm R, Eikelboom BC, May J, Bell PRF, Swedenborg J, Collin J.
Early experience with transfemoral endovascular aneurysm manage-
ment (TEAM) in the treatment of aortic aneurysms. Eur J Vasc
Endovasc Surg 1996;11:214-20.
13. Malina M, Ivancev K, Chuter TAM, Lindh M, Länne T, Lindblad B,
et al. Changing aneurysmal morphology after endovascular grafting:
relation to leakage or persistent perfusion. J Endovasc Surg 1997;4:
23-30.
14. Resnikoff M, Darling C, Chang BB, Lloyd WE, Patty PS, Leather RP,
et al. Fate of the excluded abdominal aortic aneurysm sac: long-term
follow-up of 831 patients. J Vasc Surg 1996;24:851-5.
15. White R, Donayre C, Walot I, Stewart M. Abdominal aortic aneurysm
rupture following endoluminal graft development: report of a pre-
dictable event. J Endovasc Ther 2000;7:257-62.
16. Rhee RY, Eskandari MK, Zajko AB, Makaroun MS. Long-term fate of
the aneurysmal sac after endoluminal exclusion of abdominal aortic
aneurysms. J Vasc Surg 2000;32:689-96.
17. Görich J, Rilinger N, Sokiranski R, Krämer S, Schütz A, Sunder-
Plassmann L, et al. Embolization of type II endoleaks fed by the infe-
rior mesenteric artery: using the superior mesenteric artery approach.
J Endovasc Ther 2000;7:297-301.
18. Harris PL, Buth J, Mialhe C, Myhre HO, Norgren L. The need for
clinical trials for endovascular abdominal aortic aneurysm stent graft
repair: the EUROSTAR project. J Endovasc Surg 1997;4:72-7.
19. Buth J, Laheij RJF. Early complications and endoleaks after endovas-
cular abdominal aortic aneurysm repair: report of a multicenter study.
J Vasc Surg 2000;31:134-46.
20. Harris PL, Vallabhaneni SR, Desgranges P, Becquemin JP, van
Marrewijk C, Laheij RJF. Incidence and risk factors of late rupture,
conversion, and death after endovascular repair of infrarenal aortic
aneurysms: the EUROSTAR experience. J Vasc Surg 2000;32:739-49.
21. Alimi YS, Chakfe N, Rivoal E, Slimane KK, Valerio N, Riepe G, et al.
Rupture of an abdominal aortic aneurysm after endovascular graft
placement and aneurysm size reduction. J Vasc Surg 1998;28:178-83.
22. Torsello GB, Klenk E, Kasprzak B, Umscheid T. Rupture of abdomi-
nal aortic aneurysm previously treated by endograft stent-graft. J Vasc
Surg 1998;28:184-7.
23. Krohg-Sørensen K, Brekke M, Drolsum A, Kvernebo K. Periprosthetic
leak and rupture after endovascular repair of abdominal aortic
aneurysm: the significance of device design for long-term results. J Vasc
Surg 1999;29:1152-8.
24. May J, White GH, Waugh R, Chaufour X, Stephen MS, Yu W, et al.
Rupture of abdominal aortic aneurysms: a concurrent comparison of
outcome of those occurring after endoluminal repair versus those
occurring de novo. Eur J Vasc Endovasc Surg 1999;18:344-8.
25. Walker SR, Macierewicz J, Elmarasy NM, MacSweeney ST, Greason
RHS, Whitaker SC, et al. Mortality rates following endovascular repair
of abdominal aortic aneurysms. J Endovasc Surg 1999;6:233-8.
26. Politz JK, Newman VS, Stewart MT. Late abdominal aortic aneurysm
rupture after AneuRx repair: a report of three cases. J Vasc Surg
2000;31:599-606.
27. White GH, May J, Waugh RC, Chaufour X, Yu W. Type III and type
IV endoleak: toward a complete definition of blood flow in the sac
after endoluminal AAA repair. J Endovasc Surg 1998;5:305-9.
28. Gilling Smith G, Brennan J, Harris PL, Bakran A, Gould D,
McWilliams R. Endotension after endovascular aneurysm repair: defi-
nition, classification, and strategies for surveillance and intervention. J
Endovasc Surg 1999;6:305-7.
29. White GH, May J, Petrasek P, Waugh R, Stephen M, Harris J.
Endotension: an explanation for continued AAA growth after success-
ful endoluminal repair. J Endovasc Surg 1999;6:308-15.
30. May J, White GH, Yu W, Waugh RC, Stephen MS, Harris JP. A
prospective study of changes in morphology and dimensions of
abdominal aortic aneurysms following endoluminal repair: a prelimi-
nary report. J Endovasc Surg 1995;2:343.
31. Matsumura JS, Pearce PH, McCarthy WJ, Yao JST. Reduction of aor-
tic aneurysm size: early results after endovascular graft placement. J
Vasc Surg 1997;25:113-23.
32. Armon MP, Yusuf SW, Whitaker SC, Gregson RHS, Wenham PW,
Hopkinson BR. Thrombus distribution and changes in aneurysm size
following endovascular aneurysm repair. Eur J Vasc Endovasc Surg
1998;16:472-6.
33. Broeders IAMJ, Blankensteijn JD, Gvakharia A, May J, Bell PLF,
Swedenborg J, et al. The efficacy of transfemoral endovascular
aneurysm management: a study on size changes of the abdominal
aorta during mid-term follow-up. Eur J Vasc Endovasc Surg 1997;
14:84-90.
34. Malina M, Länne T, Ivancev K, Lindblad B, Brunkwall J. Reduced
pulsatile wall motion of abdominal aortic aneurysms after endovascu-
lar repair. J Vasc Surg 1998;27:624-31.
35. Schurink GWH, Aarts NJM, Wilde J, Van Baalen JM, Chuter TAM,
Schultze Kool LJ, et al. Endoleakage after stent-graft treatment of
abdominal aneurysm: implications on pressure and imaging—an in
vitro study. J Vasc Surg 1998;28:234-41.
36. Resch T, Ivancev K, Brunkwall J, Nirhov N, Malina M, Lindblad B.
Mid-term changes in aortic aneurysma morphology after endovascu-
lar repair. J Endovasc Ther 2000;7:279-85.
37. Illig KA, Green RM, Ouriel K, Riggs P, Bartos S, DeWeese JA. Fate
of the proximal aortic cuff: implications for endovascular aneurysm
repair. J Vasc Surg 1997;26:492-501.
38. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acker
CW, et al. For the abdominal aortic aneurysm detection and manage-
ment VA cooperative study group. Variability in measurement of
abdominal aortic aneurysms. J Vasc Surg 1995;21:945-52.
39. Ivancev K, Malina M, Lindblad B, Chuter TA, Brunkwall, Lindh M, et
al. Abdominal aortic aneurysms. Experience with the Ivancev-Malmö
endovascular system for aortomonoiliac stentgrafts. J Endovasc Surg
1997;4:242-51.
40. Cuypers PWM, Laheij RJF, Buth J. Which factors increase the risk of
conversion to open surgery following endovascular abdominal aortic
aneurysm repair? Eur J Vasc Endovasc Surg 2000;20:183-9.
41. May J, White GH, Yu W, Sieunarine K. Importance of plain X-ray in
endoluminal aortic graft surveillance. Eur J Vasc Endovasc Surg
1997;13:202-6.
42. Riepe G, Heilberger P, Umscheid T, Chafke N, Raithel D, Stelter W,
et al. Frame dislocation of body middle rings in endovascular stent
tube grafts. Eur J Vasc Endovasc Surg 1999;17:28-34.
43. Ahn SS, Rutherford RB, Johnston KW, May J, Veith FJ, Baker JD, et
al. Reporting standards for infrarenal endovascular abdominal aortic
aneurysm repair. J Vasc Surg 1997;25:405-10.
Submitted Feb 14, 2001; accepted May 30, 2001.
JOURNAL OF VASCULAR SURGERY
472 van Marrewijk et al March 2002
JOURNAL OF VASCULAR SURGERY
Volume 35, Number 3 van Marrewijk et al 473
Appendix. Participants from 87 institutions who contributed the data of this EUROSTAR study
Location of institution Participant Location of institution Participant
Austria
Vienna Prof G. Kretschmer
Belgium
Gilly Dr H. Massin
Leuven Prof A. Nevelsteen
Bonheiden Dr P. Peeters
Turnhout Dr P. Stabel
Wilrijk/Antwerpen Dr M. van Betsbrugge
St Truiden Dr F. van Elst
France
Lyon Dr B. Age
Nancy Dr C. Amicabile
Paris Prof J. P. Becquemin and
Prof J. C. Gaux
Nimes Dr Cardon
St Etienne Prof J. P. Favre
Toulouse cedex Dr C. Giraud
St Laurant du Var Prof P. Kreitmann
Grenoble Dr J. L. Magne and
Dr P. Meaulle
Montpellier Prof C. Marty-Ane
Nanterre Dr J. Marzella
Draguignan Dr C. Mialhe
Marseille Dr P. L. Piquet
Toulouse Prof H. Rousseau
Lille cedex Dr M. A. Vasseur
Germany
Mainz Dr C. Düber
Düsseldorf Dr R. Kolvenbach
Hamburg Prof H. Kortmann
Munchen Prof P. Maurer
Ulm Dr R. Pamler
Oldenburg Dr C. Ratusinski
Frankfurt Prof W. Stelter
Freiburg Dr P. Uhrmeister
Bonn Dr A. Viehofer
Hanover Dr G. Voshage
Koblenz Dr R. Wickenhoefer
Greece
Athens Prof P. Balas
Ireland
Dublin Dr S. Sultan
Israel
Tel Aviv Prof B. Morach
Italy
Perugia Prof P. Cao
Luxemburg
Luxemburg Dr P. Berg
Monaco
Monaco Dr C. Mialhe
The Netherlands
Amsterdam Dr R. Balm and Dr A. Vahl
Nijmegen Dr W. B. Barendrecht 
and Dr J. van Vliet
Utrecht Dr J. Blankensteijn
Eindhoven Dr J. Buth
Veldhoven Dr J. A. Charbon
Den Haag Dr A. de Mol van Otterloo 
and Dr H. van Overhagen
Rotterdam Dr A. de Smet, Dr A. van der Ham, 
and Dr M. van Sambeek
Arnhem Dr W. de Vries
Groningen Dr H. van Dop and Dr E. Verhoeven
Enschede Dr R. Geelkerken
Tilburg Dr J. Hamming and Dr S. Kranendonk
Zwolle Dr P. Jörning
Delft Dr J. Koning
Nieuwegein Dr F. Moll
Maastricht Dr G. Schurink
Leiden Prof J. van Bockel
Norway
Oslo Prof A. Kroeze and Prof K. Kvernebo
Trondheim Prof H. Myhre
Poland
Lublin Prof J. Michalak
Spain
Madrid Dr E. Criado, 
Dr J. Sanchez-Corral, 
and Dr D. Stabel
Donostia San Sebastian Dr M. de Blas
Leon Dr R. Fernandez-Samos Gutierrez
Pamplona Dr L. Fernandez Alonso
Lugo Dr J. Pulpeiro
Barcelona Dr V. Riambau
Sweden
Lund Prof L. Norgren
Stockholm Dr J. Swedenborg
Switzerland
Zurich Dr M. Enzler
United Kingdom
Chester Dr G. Abbott
Manchester Dr R. Asleigh
Bristol Dr R. Baird
Bournemouth Dr S. Darke
Glasgow Dr R. Edwards
Hull Dr D. Ettler
Liverpool Dr P. Harris
London Dr J. Wolfe
New Castle-Upon-Tyne Dr M. Wyatt
